- CEO
- Dong-Min Kim
- Full Time Employees
- 72
- Sector
- Technology services
- Industry
- Packaged software
- Address
- #204, 10, Yangcheongsongdae-gil Cheongju-si NC South Korea
- IPO Date
- Dec 11, 2019
- Business
- JLK, Inc. JLK, Inc. (322510.KQ) develops and provides AI-driven medical diagnosis solutions, focusing on brain disorders, cancer detection, and healthcare data management; its core offerings include the MEDIHUB STROKE total solution for ischemic stroke, hemorrhagic stroke, brain aneurysm analysis via CT, CTP, MRI, MRA imaging; dementia and brain aging tools like ATROSCAN; cancer solutions such as JBS-01K for stroke, JPC-01K for prostate cancer, JVIEWER-X for chest X-ray, JLD-01K for chest CT, JBD-01K for breast cancer, JDP-01A for prostate pathology, and digital pathology platforms; additional services encompass MEDIHUB TELE for AI-integrated telemedicine, Hello Data platforms for medical, autonomous driving, and industrial data management, and AI security solutions. The company operates primarily in South Korea with global expansions through subsidiaries in Japan (JLK Inspection Japan) and the US (JLK Inspection USA), holding over 60 regulatory certifications including MFDS Korea, PMDA Japan, Europe CE, Thai FDA, and recently FDA clearance for its subdural hemorrhage detection tool, alongside approvals in Indonesia, Turkey, New Zealand, Vietnam, and Malaysia; it targets hospitals, physicians, and telemedicine users worldwide via partnerships with over 23 university hospitals and entities like Japan's DoctorNet for lung solutions and Clinton Health Access Initiative for TB screening. Founded in 2014 and headquartered at JLK Tower in Seoul, South Korea, with prior facilities in Cheongju, JLK, Inc. lists on KOSDAQ since December 2019 as the first AI medical firm to do so; recent developments feature establishment of subsidiary JLK BIO in 2021 for AI drug discovery via DeepHits platform, FDA clearance for SDH detection in 2025 bringing total US approvals to seven with eight more submissions planned, innovative medical device designations for JBS-01K, national R&D project wins for AI cancer pathology, and regulatory sandbox approval for overseas telemedicine.